Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma

F14512 is a new topoisomerase II inhibitor containing a spermine moiety that facilitates selective uptake by tumor cells and increases topoisomerase II poisoning. F14512 is currently in a phase I/II clinical trial in patients with acute myeloid leukemia. The aim of this study was to investigate F145...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2015-12, Vol.21 (23), p.5314-5323
Hauptverfasser:	Tierny, Dominique, Serres, François, Segaoula, Zacharie, Bemelmans, Ingrid, Bouchaert, Emmanuel, Pétain, Aurélie, Brel, Viviane, Couffin, Stéphane, Marchal, Thierry, Nguyen, Laurent, Thuru, Xavier, Ferré, Pierre, Guilbaud, Nicolas, Gomes, Bruno
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal biology Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - pharmacology Biomarkers Cell Line, Tumor Dog Diseases - drug therapy Dog Diseases - metabolism Dog Diseases - pathology Dogs Drug Evaluation, Preclinical Female Histones - metabolism Humans Life Sciences Lymphoma - veterinary Male Neoplasm Staging Podophyllotoxin - adverse effects Podophyllotoxin - analogs & derivatives Podophyllotoxin - pharmacokinetics Podophyllotoxin - pharmacology Topoisomerase II Inhibitors - adverse effects Topoisomerase II Inhibitors - pharmacokinetics Topoisomerase II Inhibitors - pharmacology Treatment Outcome Veterinary medicine and animal Health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!